Thwarting dyskinesia by targeting mTORC1.


In a mouse model of Parkinson's disease, new evidence shows that l-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1… (More)
DOI: 10.1126/scisignal.280pe42


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics